Welcome to THERALPHA - Innovative Therapeutics for Pain Managment

Theralpha is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment pain. Our lead product, THA903, is designed to address acute pain by sublingual administration. We have three additional product candidates in preclinical development. We are advancing next generation pain drugs based on scientifically validated Acid Sensing Ion Channel (ASIC) pathways.

Current therapies are often inadequate, have side effects, or are under-prescribed due to the dangers of addiction. There has been a lack of clinical breakthroughs in recent years, instead of Current therapies are often inadequate or have side effects, and there has been lack of clinical breakthroughs.

Theralpha aims to develop its pipeline to address unmet medical need in pain, a significant economic burden where more than 300 million people worldwide suffer. The chronic pain market is currently valued at $30 billion and is forecast to reach more than $47 billion by 2023.

We currently have four product candidates in development.

December 26, 2011
Green light (Tox, manufacturing, ...) to the start of the PK – PD for THA902.
THA902 is in co-development with Flamel Technologies (NASDAQ: FLML)

December 21,2011
Subalgic started for THA903. PK will start in April.

November 17, 2011
New Publication demonstrates inhibitory effect of THA902 on Nav 1.8 Channel
A new publication emanating from the University of Lausanne (published in The British Journal of Pharmacology) has demonstrated that the THA902 has an inhibitory effect on Nav 1.8 channel as well as its well-known inhibitory activity on the ASIC3 channel.
This is great news for this compound particularly relevant for the treatment of inflammatory pain. THA902 is in preclinical stage in co-development with Flamel Technologies. (NASDAQ: FLML)

September 6, 2011
Theralpha receives major grant for pain drug development.
2,55 million Euros granted to SubAlgic, a collaborative R&D consortium headed by Theralpha

June 23, 2011
Theralpha Expands Scientific & Medical Advisory Board.
Theralpha, added Professor Alain Echalier and Professor Claude Dubray to its Scientific & Medical Advisory Board.

June 7, 2011,
Theralpha announced the appointment of Damian Marron to its board of directors.
Damian Marron is the Chief Executive Officer of Trophos, He served as Executive Vice President of Corporate Development of Nicox More… CP_Newboardmember.pdf PR_Newboardmember.pdf

May 9, 2011,
Theralpha Announces Collaboration and Business Agreement with Flamel Technologies to develop controlled-release formulation of analgesic peptide PR_Theralpha_Flamel_051101.pdf

Theralpha receives the labeling of the cluster Eurobiomed for his project SubAlgic in the treatment of acute pain (using its compound THA903 a small natural peptide, which operates sublingually).

April 2011,
Theralpha gets 1 million euros of public support under a RDI / OSEO project for the preclinical development of a drug candidate for the treatment of pain.

The Ernst Jung Medal for Medicine in Gold 2011 is awarded to Prof. Michel Lazdunski (Institut de Pharmacologie Moléculaire et Cellulaire, CNRS Sophia Antipolis France). ww.jung-stiftung.de

UPCOMING PARTNERING EVENTS

Meet Theralpha in Zermatt, Switzerland for Natural Peptides to Drugs
Professor Lazdunski will present 4-6 December http://www.np2d.com/
To contact : info@theralpha.com

Theralpha' CEO David Dellamonica will present at the Roche Colorado Peptide Symposium in Boulder,
Colorado, September 11-14, 2011.
To contact : info@theralpha.com
www.rochecolorado.com/ PeptideSymp/